Logo of Biovectra, a part of Agilent, featuring stylized geometric design with purple and yellow elements against a black background.

WEBINAR

WEBINAR

Unleashing the Potential of ADCs with High-Quality Bioreagents

ADCs are an advanced approach in the field of biomedicine that aims to target and treat various diseases in innovative ways, though there are often challenges which require innovative solutions for development, scale-up, and commercialization.

Particularly, when it comes to ADC manufacturing, two key challenges lie in the realms of potency testing and product purity. Furthermore, robust tools and streamlined processes are required to ensure the timely production of ADCs for clinical trials and commercial launches. Additionally, meeting regulatory standards adds another layer of complexity to the manufacturing process.

Thankfully, there are way to ensuring the highest quality outcomes for ADC projects. One such advantage lies in the utilization of cGMP grade materials, such as dehydroascorbic acid (DHAA) and tris(2-carboxyethyl phosphine) (TCEP) reagents. These high-quality materials are crucial in conjugation chemistry, facilitating efficient and precise antibody-drug conjugation.

Throughout this webinar, we’ll explore the challenges outlined above, examining their impact and potential solutions for advancing ADC manufacturing, share insights into the advantages of utilizing cGMP grade DHAA and TCEP in ADC manufacturing, and discuss the effective approaches for addressing potency testing and product purity challenges.

Attendees will gain insights Into:

I'm unable to identify or describe the person in the image. However, the image shows a person wearing a suit, smiling against a plain background.

Jean-Francois Vincent-Rocan

Director of Complex Chemistry Process Development, BIOVECTRA

A person with glasses and a beard smiles, wearing a suit jacket over a black shirt, against a plain white background.

Alex Hendry

Business Development & Marketing, BIOVECTRA

Register Below

About Us

With over 50 years of experience, we are a forward-thinking, North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.

The image features the phrase "We Care" in white with a purple and yellow heart shape, representing a focus on empathy and support.

Contact Us

Toll Free: +1 (866) 883-2872
Phone: +1 (902) 566-9116
Fax: +1 (902) 628-2045

11 Aviation Avenue,
Charlottetown, PE, C1E 0A1
Canada

Logo featuring "BIOVECTRA" in purple text with a blue and yellow abstract design, and the phrase "A part of Agilent" below.
Facebook Linkedin X-twitter

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors